Evidence map›Paper›PMID 29931698›Full record

ArticleGenetic epidemiology2018

A subregion-based burden test for simultaneous identification of susceptibility loci and subregions within.

Bin Zhu, Lisa Mirabello, Nilanjan Chatterjee

Abstract read
In one paragraph

Article in Genetic epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bin ZhuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, Maryland.ORCID 0000-0003-0172-5516
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, Maryland.
Nilanjan ChatterjeeDepartment of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Funding

Intramural NIH HHS Z99 CA999999NCI NIH HHS the Intramural Research ProgramNIH HHS
6 · The paper itself

Abstract

In rare variant association studies, aggregating rare and/or low frequency variants, may increase statistical power for detection of the underlying susceptibility gene or region. However, it is unclear which variants, or class of them, in a gene contribute most to the association. We proposed a subregion-based burden test (REBET) to simultaneously select susceptibility genes and identify important underlying subregions. The subregions are predefined by shared common biologic characteristics, such as the protein domain or functional impact. Based on a subset-based approach considering local correlations between combinations of test statistics of subregions, REBET is able to properly control the type I error rate while adjusting for multiple comparisons in a computationally efficient manner. Simulation studies show that REBET can achieve power competitive to alternative methods when rare variants cluster within subregions. In two case studies, REBET is able to identify known disease susceptibility genes, and more importantly pinpoint the unreported most susceptible subregions, which represent protein domains essential for gene function. R package REBET is available at https://dceg.cancer.gov/tools/analysis/rebet.

Indexed as

Genetic LociGenetic Predisposition to DiseaseAngiopoietin-Like Protein 4Computer SimulationGenetic VariationHumansModels, GeneticOsteosarcomaPhenotypeSequence Analysis, DNAAngiopoietin-Like Protein 4ANGPTL4 protein, humanburden testdisease susceptibility genesrare variant association studiessubset-based approach

Identifiers

PMID29931698
PMCPMC6185783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.